Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio

  • Data for EVRYSDI reinforce safety profile and efficacy in a broad spinal muscular atrophy (SMA) population, following recent EU approval
  • Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) build on safety profile and efficacy following recent CHMP opinion, including in adults with concomitant autoimmune diseases (CAIDs)
  • OCREVUS data continue to show consistent benefit on slowing disease progression in relapsing MS (RMS) and primary progressive MS (PPMS)
  • Additional presentations in Alzheimer’s disease (AD), Huntington’s disease (HD) and Parkinson’s disease (PD) continue to contribute to understanding of these complex neurological disorders

Basel, 15 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data across its growing neuroscience portfolio will be presented at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting being held virtually 19-22 June, 2021. These new and encore data demonstrate Roche’s commitment to advancing the clinical understanding of a broad range of neurological disorders with the goal of meeting the needs of people living with both the rarest and most common conditions.“

Our data at EAN and recent European regulatory milestones for EVRYSDI and ENSPRYNG reflect our continued commitment to discovering and developing breakthrough medicines for challenging neurological conditions.” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We are honoured to work with our partners and the broader community to accelerate progress across our neuroscience portfolio with the goal of transforming the lives of many people living with neurological disorders.”

Spinal Muscular Atrophy (SMA)
Roche will present updated data from across the extensive EVRYSDI™ (risdiplam) clinical development programme, designed to represent a broad spectrum of people living with SMA, including those who have previously been treated with another SMA medication.

Among the five abstracts featured, new data includes 12-month safety, pharmacodynamic and interim exploratory efficacy data from the JEWELFISH study of EVRYSDI in people previously treated with SMA-targeting therapies across a broad range of ages (1–60 years), SMA types (1–3) and SMN2 copy number (1-5).

Data from SUNFISH Part 2 supporting the safety profile and efficacy of EVRYSDI in people aged 2-25 years with SMA Types 2 or non-ambulant Type 3 after two years of treatment will also be shared, as well as updated 2-year safety and efficacy data from the pivotal FIREFISH Parts 1 and 2 showing continued improvements in survival and motor milestones in infants aged one to seven months with Type 1 SMA.

In addition, preliminary safety and efficacy data from the RAINBOWFISH study of EVRYSDI treatment in pre-symptomatic babies from birth to six weeks will be presented, along with longer-term safety data from a separate pooled analysis of the FIREFISH, SUNFISH, JEWELFISH and RAINBOWFISH trials.

EVRYSDI, the first and only at home SMA treatment, is now approved in 42 countries, including the U.S. and EU. More than 3,000 patients have been treated with EVRYSDI in clinical trials, compassionate use and real-world settings.

Neuromyelitis Optica Spectrum Disorder (NMOSD)
Roche will share three sets of data on people living with NMOSD, including an analysis of the Phase III SAkuraStar and SAkuraSky clinical trials which show ENSPRYNG® (satralizumab) significantly reduced risk of relapse vs placebo in adults with AQP4-IgG seropositive (AQP4-IgG+) NMOSD, with a favourable safety profile.

A separate pooled data analysis from the SAkura studies will also be presented, reinforcing favourable safety and efficacy of ENSPRYNG in people with NMOSD, including those with concomitant autoimmune diseases (CAIDs). Results from a new claims-based algorithm to identify people with NMOSD and NMOSD relapses in German claims data will also be shared.

ENSPRYNG is currently approved in 24 countries and has received a positive CHMP opinion as the first and only subcutaneous treatment for adults and adolescents with AQP4-IgG seropositive NMOSD in the EU, enabling home dosing by a person with NMOSD or their care partner.

Multiple Sclerosis (MS)
Four OCREVUS® (ocrelizumab) presentations will be shared, including an analysis of the Phase IIIb CASTING study in people with relapsing-remitting MS (RRMS) who had a suboptimal response to one or two prior disease-modifying therapies (DMTs). OCREVUS improved work productivity over two years, which correlated with reduced symptom burden and improvement in the physical and psychological impacts of MS.

Data from a separate subgroup analysis of the CASTING study will also be presented, continuing to show a favourable benefit-risk profile for OCREVUS and comparable safety outcomes regardless of age, type, or number of prior DMTs.

In addition, data from the OPERA and ORATORIO Phase III studies and their open-label extensions will be shared. A pooled analysis of the OPERA I and II studies, showed that OCREVUS reduced cerebellar atrophy in relapsing MS (RMS), compared with interferon beta-1a (IFN). An analysis of the open-label extension studies demonstrated that individuals initially treated with OCREVUS maintained lower cerebellar volume loss relative to baseline in both RMS and primary progressive MS (PPMS) during the open-label extension periods vs. those initially treated with comparators. OCREVUS is the first and only therapy approved for both RMS and PPMS with twice-yearly dosing, with over 200,000 patients treated globally.

Finally, a late-breaking oral abstract on risk factors for developing symptomatic or serious COVID-19 in patients treated with OCREVUS will be presented.

Alzheimer’s Disease (AD)
Roche will present an overview of the CareRing initiative, which engaged AD caregivers to input and provide guidance on trial design and protocol for the Phase IB/IIA Brain Shuttle AD trial, evaluating RG6102 in people with prodromal or mild-to-moderate AD.

RG6102 is a bispecific 2+1 monoclonal antibody that combines investigational gantenerumab with Roche’s Brain Shuttle technology. It is designed to be transported across the blood-brain barrier by engaging the transferrin receptor in order to achieve superior target engagement in the brain.

Huntington’s Disease (HD)
The protocol for a multinational qualitative study sponsored by Roche examining the burden of HD from a multidimensional, generational perspective (SEEING-HD) will be presented. Findings from this study will make an important contribution to advancing evidence-based care to improve the lives of individuals and families affected by HD.

Parkinson’s Disease (PD)
Roche will share three presentations including further results from the Phase II PASADENA study evaluating the safety and efficacy of prasinezumab in early PD. In the PASADENA study, prasinezumab was the first anti-alpha-synuclein antibody to show evidence of slowing clinical decline of PD motor signs and demonstrated a favourable safety profile. These findings warrant further investigations in the recently initiated PADOVA study, studying the effect of prasinezumab in people with early Parkinson's disease receiving symptomatic therapy. In addition, data from two studies on digital health monitoring in PD will also be presented.

The full range of data from Roche’s clinical development programme in neuroscience being presented at EAN include:

Medicine and/or Therapeutic AreaAbstract Title

Presentation Number (type), Session Title
Presentation Date
for Spinal Muscular Atrophy

FIREFISH Parts 1 and 2: 24-Month Safety and Efficacy of Risdiplam in Type 1 SMAEPR213
Motor neurone diseases 2
13:15 – 14:00
JEWELFISH: 12-month safety, pharmacodynamic and exploratory efficacy of risdiplam in non-naïve patients with SMAEPR213
Motor neurone diseases 2
13:15 – 14:00
Pooled safety data from the risdiplam clinical trial development programEPR213
Motor neurone diseases 2
13:15 – 14:00
RAINBOWFISH: A study of risdiplam in infants with presymptomatic SMAEPR213
Motor neurone diseases 2
13:15 – 14:00
SUNFISH Part 2: 24-month efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 SMAOS3005
Motor neurone disease 2
17:00 – 18:15
ENSPRYNG (satralizumab) for Neuromyelitis Optica Spectrum Disorder

Satralizumab in adults with AQP4-IgG seropositive NMOSD: Efficacy and safety results from the phase 3 SAkura studiesOS3003
Multiple Sclerosis: NMOSD
16:45 – 18:15
Satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) and concomitant autoimmune diseaseOS3003
Multiple Sclerosis: NMOSD
16:45 – 18:15
Neuromyelitis Optica Spectrum DisorderClaims-based algorithm to identify NMOSD patients and relapses in German claims dataEPO222
MS and related disorders 3
19:30 – 20:15
OCREVUS (ocrelizumab) for Multiple Sclerosis

Effect of Ocrelizumab on Cerebellar Atrophy in RMS and PPMS: Results from OPERA I/OPERA II and ORATORIOOS1016
Multiple Sclerosis: Clinical studies
17:00 – 18:30
Safety of Ocrelizumab in Patients With RRMS With Suboptimal Response to Prior DMTs: Data From the CASTING StudyOS1016
Multiple Sclerosis: Clinical studies
17:00 – 18:30
Improvements in Work Productivity and Activity Impairment in OCR-treated patients with RRMS: 2-year CASTING study dataEPR108
MS and related disorders 1
12:00 – 12:45
COVID-19 risk factors in people with multiple sclerosis treated with ocrelizumab

Late Breaking News: COVID-19/Neuro-immunology 22.06.2021
08:30 – 08:45
RG6102 for Alzheimer’s Disease Engaging the Alzheimer’s disease (AD) CareRing caregiver community in designing the Phase IB/IIA Brainshuttle AD trialEPO323
Neurology and arts, History of neurology, Education in neurology
14:00 – 14:45
Huntington’s DiseaseA Multinational Qualitative Study Examining the Intergenerational Burden of Huntington’s Disease (part of SEEING-HD)EPO216
Cognitive neurology/neuropsychology 2
19:30 – 20:15
Parkinson’s Disease

Phase II PASADENA Part 1 Week 52 results: Evaluating safety and efficacy of prasinezumab in early Parkinson's
Movement Disorders: Treatment
15:00 - 16:30
Roche Parkinson’s Disease Mobile Application v2 detects potential disease modifying effect of prasinezumabOS2010
Movement Disorders: Treatment
15:00 - 16:30
Reliability and validity of passively measured gait gestures from smartphones and
smartwatches in Parkinson’s disease
Movement Disorders: Clinical
17:00 - 18:30

About EVRYSDI™ (risdiplam)
EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier designed to treat SMA by increasing production of the survival of motor neuron (SMN) protein. SMN protein is found throughout the body and is critical for maintaining healthy motor neurons and movement. EVRYSDI is administered daily at home in liquid form by mouth or by feeding tube.

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved EVRYSDI for the treatment of SMA in adults and children 2 months of age and older. EVRYSDI was granted PRIME designation by the EMA in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. At this time, EVRYSDI has been approved in seven countries and submitted in 57, including the EU 27 and Norway and Iceland.

About ENSPRYNG® (satralizumab)
ENSPRYNG, which was designed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. The cytokine IL-6 is believed to be a key driver in NMOSD, triggering the inflammation cascade and leading to damage and disability. ENSPRYNG was designed using novel recycling antibody technology which, compared to conventional technology, allows for longer duration of the antibody and subcutaneous dosing every four weeks.

Positive Phase III results for ENSPRYNG, as both monotherapy and in combination with baseline immunosuppressive therapy, suggest that IL-6 inhibition is an effective therapeutic approach for NMOSD. The Phase III clinical development programme for ENSPRYNG included two studies: SAkuraStar and SAkuraSky.

ENSPRYNG is currently approved in 24 countries, including the United States, Canada, Japan, China and Switzerland.

ENSPRYNG has been designated as an orphan drug in the U.S., Europe and Japan. In addition, it was granted Breakthrough Therapy Designation for the treatment of NMOSD by the FDA in December 2018.

About OCREVUS® (ocrelizumab)
OCREVUS is the first and only therapy approved for both RMS (including clinically isolated syndrome, RRMS and active, or relapsing, SPMS) and PPMS, with dosing every six months. OCREVUS is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved.

OCREVUS is administered by intravenous infusion every six months. The initial dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions.

About Roche in Neuroscience
Neuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.

Roche is investigating more than a dozen medicines for neurological disorders, including spinal muscular atrophy, multiple sclerosis, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Duchenne muscular dystrophy and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail:

Dr. Nicolas Dunant
Phone: +41 61 687 05 17
Patrick Barth
Phone: +41 61 688 44 86
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
Jon Kaspar Bayard
Phone: +41 61 68-83894
Dr. Sabine Borngräber
Phone: +41 61 68-88027
Dr. Bruno Eschli
Phone: +41 61 68-75284
Dr. Birgit Masjost
Phone: +41 61 68-84814
Dr. Gerard Tobin
Phone: +41 61 68-72942
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Financière de Tubize - 2021 halfyear financial report2.8.2021 08:00:00 CEST | Press release

Press release 2 August 2021 Embargo till 08:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Brussels Contact: Eric Nys, day-to-day management, 2021 half-year financial report Regulated information 2 August 2021 The board of directors of Financière de Tubize has issued the 2021 half-year financial report. This report is available on the website Profit for the period in accordance with Belgian accounting standards: € 85,0 million,Profit for the period in accordance with International Financial Reporting Standards (IFRS): € 204,8 million,Dividend received from UCB: € 86,5 million (€ 1,27 per share, an increase of 2,4% compared to 2020),Dividend paid to shareholders of Financière de Tubize of € 30,3 million (€ 0,68 per share, an increase of 9,6% compared to 2020), Decrease of outstanding bank borrowings from € 33,5 million at 31 December 2020 to € 0,0 at 30 June 2021,Acquisition of 257.000 UCB shares, increasing the hold

Biotalys announces end of Stabilization Period and the partial exercise of the Over-allotment Option in respect of 712,942 Shares in connection with its Initial Public Offering2.8.2021 07:00:00 CEST | Press release

Ghent, BELGIUM, Aug. 02, 2021 (GLOBE NEWSWIRE) -- This announcement is not an offer to invest in the shares (the “Shares”) of Biotalys. An investment in the Shares can only be based on the prospectus (the “Prospectus”) Biotalys has issued in connection with the offering of its Shares and which has, subject to the certainlimitations, been made available on the Company’s website prospective investors must read the entire prospectus in order to fully understand the potential risks and rewards associated with the decision to invest in the Shares. Prospective investors should read in particular the section on “Risk Factors” for a discussion of certain factors which should be considered in connection with an investment in the Shares, includingthe following risks: (i) Biotalys has never brought a product to the market. All but one of Biotalys’ product candidates are still in early stages of discovery. Only one product candidate is in the registration phase, but

TGS Announces NOAKA Ocean Bottom Node Seismic Survey on the Norwegian Continental Shelf2.8.2021 07:00:00 CEST | Press release

OSLO, Norway (2 August 2021) - TGS, a global provider of energy data and intelligence, today announced a new Ocean Bottom Node (OBN) seismic survey on the Norwegian Continental Shelf (NCS). The 437 square kilometer survey will be acquired in the NOAKA area, between Oseberg and Alvheim in the Norwegian North Sea, containing both held and open acreage. This region has seen significant Infrastructure-Led Exploration (ILX) activity in recent years and includes the development of the NOAKA fields, one of the largest developments on the NCS, with recoverable reserves of more than 500 million barrels of oil equivalents. TGS expects to emulate the recent success of the TGS-AGS Utsira OBN project in the North Sea (the first large-scale, densely sampled OBN survey for exploration) and will apply the learnings from TGS’ ongoing reprocessing of Utsira, including the extraction and use of ultra-long offset signal for FWI-based model building. As with Utsira, the NOAKA survey will utilize full azimu

Yara continues its transformation with divestment of Salitre phosphate mining project in Brazil1.8.2021 21:00:00 CEST | Press release

Oslo, 1 August 2021: Yara has signed a Share Purchase Agreement with EuroChem to sell its Salitre phosphate mining project for a cash consideration of USD 410 million. Yara’s ongoing transformation has a strategic focus on food solutions, premium products and enabling the hydrogen economy. Salitre remains an attractive project, but as previously communicated the project progress has been impacted by Covid 19, and significant construction time and capital expenditure remains to reach completion. The Salitre divestment therefore supports Yara’s transformation by reallocating capital and risk appetite in the coming years towards Yara’s strategic focus areas. “This transaction allows us to further sharpen our strategic focus, based on our strong competitive edges. Yara Brazil will continue to play an essential role in this growth agenda, and this transaction enables that growth to be driven with a sharper downstream focus,” said Svein Tore Holsether, President and Chief Executive Officer o

Scientists Narrow Search For Mysterious Mad Trapper To Sweden30.7.2021 23:21:41 CEST | Press release

EDMONTON, Alberta and HOUSTON, July 30, 2021 (GLOBE NEWSWIRE) -- This month marks the 90th anniversary of the arrival of the fugitive known as ‘The Mad Trapper of Rat River’ to the Canadian North and the revelation of an important new clue to identifying the mysterious fugitive. Following the unprovoked shooting of RCMP Constable A.W. King in December 1931, the unknown criminal who identified himself by the pseudonym Albert Johnson led an RCMP posse on seven-week manhunt across the desolate Arctic landscape. During the pursuit, the Mad Trapper shot and killed Constable E. Millen. With the help of indigenous guides the Mad Trapper was located and killed during a gun battle on the Eagle River on February 17, 1932. Despite the RCMP releasing photos of the Mad Trapper and receiving hundreds of tips from around the world his identity was never established In 2007, Myth Merchant Films of Alberta Canada secured permission for a team of forensic experts to exhume the body of the Mad Trapper in

KBC Group: KBC remains strongly capitalised under 2021 EU-wide EBA stress test30.7.2021 18:15:00 CEST | Press release

Press Release Outside trading hours - Regulated information* Brussels, 30 July 2021 (6.15 p.m. CEST) KBC remains strongly capitalised under 2021 EU-wide EBA stress test KBC notes the announcements made today by the European Banking Authority (EBA) regarding the results of the 2021 EU-wide stress test. A brief set of slideson the KBC data is available at The impact of the stress test on KBC’s fully loaded Common Equity Tier-1 (CET1) ratio of 17.58% at year-end 2020 caused this ratio to increase by 1.92 percentage points to 19.50% at year-end 2023 under the base scenario. Under the adverse scenario, KBC’s fully loaded CET1 ratio would fall by 3.51 percentage points to 14.07%1. KBC’s leverage ratio, which stood at 6.42% at year-end 2020, would increase to 7.09% under the base scenario and decrease to just 5.53% under the adverse scenario. Commenting on today’s announcements, Johan Thijs, KBC Group CEO had this to say: ‘The results of this regular, theoretical exercise conduct

EBA reports on outcome of 2021 EU-wide stress test30.7.2021 18:10:23 CEST | Press release

EBA reports on outcome of 2021 EU-wide stress test ING Group was subject to the 2021 EU-wide stress test conducted by the European Banking Authority (EBA), in cooperation with the European Central Bank (ECB), the European Systemic Risk Board (ESRB) and De Nederlandsche Bank. ING Group notes the announcements made today by the EBA on the stress test and fully acknowledges the outcomes of this exercise. The 2021 EU-wide stress test does not contain a pass/fail threshold and instead is designed to be used as an important source of information for the purposes of the Supervisory Review and Evaluation Process. The results will assist competent authorities in assessing ING Group’s ability to meet applicable prudential requirements under stressed scenarios. The adverse stress test scenario was set by the ECB/ESRB and covers a three-year time horizon (2020-2023). The stress test has been carried out applying a static balance sheet assumption as at December 2020, and therefore does not take int